##### 简要描述
- ClinicalTrials.gov数据库涵盖了目前美国临床试验数据库(ClinicalTrials)登记的所有信息,可以查询各企业登记药品的临床试验题目,登记号,招募状态,干预措施,临床试验方案,适应症,申办者等信息.
##### 请求URL
- ` https://api.wuxuwang.com/us_clinical_info`
##### 请求方式
- POST
##### 参数
|参数名|必选|示例|类型|说明|
|:---- |:---|:----- |:----- |----- |
|registrationNo |否 |CTR20200896 |string |登记号 |
|testSubject |否 |评估HN0037片的安全性 |string | 试验题目 |
|indication |否 |Cholangiocarcinoma, Intrahepatic |string | 适应症 |
|companyName |否 |Fudan University |string | 申办者 |
|pageNum |否 |1 |int | 当前页码,默认 1 |
##### 返回示例
```
{
"code":200,
"message":"Success",
"result":{
"data":[
{
"companyName":"Fudan University",
"cooperator":"Emory University",
"testSpecialtySubject":"PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant",
"registrationNo":"HUASHAN006",
"sketch":"The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection",
"description":"Cholangiocarcinoma has a low incidence, accounting for only 3% of gastrointestinal malignancies worldwide, but with an increasing trend in recent years.Cholangiocarcinoma is extremely malignant, and the 5-year survival rate for patients who cannot undergo curative resection at advanced stages is less than 10%. Surgical resection represents the only curative opportunity for biliary tract cancer, but only 1 5% - 20% of patients can undergo surgical resection; however, even patients who undergo curative surgical resection have a high rate of postoperative metastasis recurrence, and effective treatment strategies are lacking after metastasis recurrence.The median postoperative survival time is only 18-30 months and the 5-year survival rate is also only 20-35%.Among them, patients with high-risk postoperative recurrence who are resected but have positive lymph nodes or margins have further reduced survival, and no targeted effective postoperative adjuvant therapy is available, becoming another important reason that hampers the long-term survival of surgical patients. For unresectable or advanced cholangiocarcinoma, GEMOX, a two drug combination regimen of gemcitabine plus cisplatin, can be used as a first-line chemotherapy regimen, but the first-line regimen of postoperative adjuvant chemotherapy is currently not uniformly recommended.Previous adjuvant chemotherapy...",
"researchType ":"Interventional",
"testByStages ":"Phase 1",
"researchDesign":"Non-Randomized",
"indication":"Cholangiocarcinoma, Intrahepatic",
"interveningMeasure ":"Drug Capecitabine",
"testGroup":"Capecitabine Active Comparator",
"recruitmentStatus":"Not yet recruiting",
"sampleNum":"40",
"qualificationCriteria":"Inclusion Criteria: 1. Participants must have histologically confirmed salivary gland carcinoma (any histologic subtype, including ACC) with evidence of recurrent, metastatic or advanced, unresectable disease",
"sex":"All",
"minAge":"18",
"maxAge":"45",
"volunteer":"No",
"contacts":"Masonic Cancer Center, University of Minnesota",
"researcher":"Glenn J Hanna, MD;Principal Investigator;Dana-Farber Cancer Institute",
"countrie":"United States",
"mainOutcome":"Number of evaluable patients with objective response as measured by RECIST version 1.13-24 months ",
"minorOutcome":""
}
],
"pageSize":10,
"totalCount":10,
"pageNum":1
}
}
```
##### 返回说明
|参数|类型|描述|
|:-------|:-------|:-------|
| companyName | string| 申办者名称 |
| cooperator | string| 合作者 |
| testSpecialtySubject | string| 试验专业题目 |
| registrationNo | string| 登记号 |
| sketch | string| 简述 |
| description | string| 详情描述 |
| researchType | string| 研究类型 |
| testByStages | string| 试验分期 |
| researchDesign | string| 研究设计 |
| indication | string| 适应症 |
| interveningMeasure | string| 干预措施 |
| recruitmentStatus | string| 招募状态 |
| sampleNum | string| 样本数 |
| qualificationCriteria | string| 资格标准 |
| sex | string| 性别 |
| minAge | string| 最小年龄 |
| maxAge | string| 最大年龄 |
| volunteer | string| 健康志愿者 |
| contacts | string| 联系人 |
| researcher | string| 研究者 |
| countrie | string| 所在地 |
| mainOutcome | string| 主要结果指标 |
| minorOutcome | string| 次要结果指标 |
- 更多返回错误代码请看首页的错误代码描述
